Surrogate markers of angiogenesis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Anti-angiogenic drugs have entered the anticancer drug arsenal, but there is a clear need to identify patients who are likely to benefit from this therapeutic strategy. Circulating endothelial cells (CECs) and progenitors (CEPs) have been reported to be modulated in cancer patients. At the preclinical level, CEC and CEP kinetics correlate well with several standard laboratory angiogenesis assays, which cannot be used in humans. At the clinical level, CEC kinetics and viability may correlate with clinical outcomes in cancer patients treated using anti-angiogenic therapeutic strategies. Thus, CEC and CEP measurement has potential as a surrogate marker for monitoring anti-angiogenic treatment/drug activity and helping to determine the optimal biological dosage of anti-angiogenic drugs.

Original languageEnglish
Title of host publicationTumor Angiogenesis: Basic Mechanisms and Cancer Therapy
PublisherSpringer Berlin Heidelberg
Pages795-808
Number of pages14
ISBN (Print)9783540331766
DOIs
Publication statusPublished - 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Surrogate markers of angiogenesis'. Together they form a unique fingerprint.

Cite this